The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•30 March 2026•

1 min read

Teva Gains FDA Approval for New Biosimilar and Regulatory Acceptance for Xolair Candidate

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1The U.S. FDA approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia.

2The U.S. FDA and European Medicines Agency (EMA) accepted filing applications for a biosimilar candidate to Xolair.

Version History

1 additional source confirmed this story

Teva Pharmaceutical Industries (TEVA) announced that the U.S. FDA has approved PONLIMSI as a biosimilar to the reference product Prolia. In addition to this approval, the company received filing acceptances for its Xolair biosimilar candidate from both the FDA and the European Medicines Agency (EMA). These milestones represent a significant execution of Teva's "Pivot to Growth" strategy, which focuses on strengthening its biosimilar portfolio. The dual regulatory progress in the U.S. and Europe highlights the company's commitment to expanding its global market footprint. Analysts view these developments as a major boost to Teva's future revenue potential and competitive positioning in the pharmaceutical sector. The expansion of its biosimilar pipeline is expected to be a key driver for the company's long-term financial performance.